

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

(A joint stock limited company incorporated in the People's Republic of China)

Stock code: 1558.HK

2020 Interim Results Presentation













😃东陽光药



Summary of the Year



Revenue decreased 32% y-o-y to RMB 2,084 million.

EBITDA decreased 29% y-o-y to RMB 930million.

Adjusted net profit¹ decreased 37% y-o-y to RMB 696million.



Expanding OTC pharmacies channel, covering over 380,000 pharmacies up to date and contributed 29% in Kewei revenue.

E-commerce channel expansion showed rapid progress and contributed 13% in Kewei revenue.



Obtained marketing approvals for entecavir tablets, esomeprazole magnesium enteric-coated capsule and olanzapine orally disintegrating tablets.

First biologic product of the Group human recombinant insulin has been approved to market.

Carried out H shares full circulation reform and the application for converting and listing domestic shares has been approved by CSRC².



Contents







3

4

Business Review






Financial Analysis




Key products cemented revenue foundation while long-term growth further reinforced by acquired generics and continuous expansion of product portfolio




- 东防羌行

Covid-19 outbreak spread nationwide since beginning of 2020, leading to declined population mobility, influenza cases and outpatient visits

Number of reported influenza cases in China





Outpatient visits in hospitals in China¹ (millions)

Revenue during the period recorded at RMB 2,084 million, representing a decrease of 32% y-o-y, which was primarily attributed to decline in sales revenue of key products Kewei capsules and granules.

- Since 2019 year-end, prevention measures have been implemented in order to combat the outbreak, which significantly restricted population mobility and visits in hospitals.
- 2 Diagnosis of flu has been based on clinical manifestation and previous exposure during flu season prior to the outbreak, whereas lately patients exhibited fever were required to quarantine in order to control the spread of outbreak, resulting in fewer flu cases.

1 China NHC data. Jan-Feb data does not include Hubei province and clinics in rural area

Steadily established concept of preventing and treating flu while sales of Kewei continued to expand in ex-Guangdong regions, there remains significant market potential for influenza medications



- Covid-19 outbreak has drawn public attention towards respiratory tract diseases, especially for the high-risk group, leading to reinforcement on the awareness of preventing and treating influenza proactively.
- As outbreak prevention becomes a new norm, preventing cross-infection during flu season has become the emphasis of public health matters. Several provincial Health Commissions have issued guidance on mandatory medication preparation, in which oseltamivir has been listed.
- Increased public awareness of prophylactic measures towards influenza. Concept of having Kewei stocked at home began to popularize.

Top 10 provinces by Kewei sales in 1H

	Province	Population proportion ¹	2020 Contribution ²	2019 Contribution ²		
	Guangdong	7.8%	13.4%	15.3%		
	Shandong	7.2%	11.4%	9.9%		
	Jiangsu	5.9%	8.3%	7:5%		
	Henan	7.1%	6.5%	6.7%		
٦.,	Zhejiang	4.1%	5.5%	5.7%		
	Anhui	4.5%	5.5%	4.2%		
	Hubei	4.3%	4.6%	5.5%		
	Fujian	3.0%	4.4%	4.9%		
	Hunan	4.9%	4.0%	4.9%		
	Jiangxi	3.0%	4.0%	2.4%		
	15% F 10% S%	Kewei sales correlated to local population, growth potential remains in areas with unsaturated treatment.				
	∞ 0% 0%	2% 4	-% 6%	8% 10% 7		
	Population proportion					



¹ Population data based on 2010 6th National Census 2 Data does not include sales from OTC pharmacies 3 WHO

Sales team of 3,442 staff in multiple channels provides robust support for sales growth, of which the number and structure are constantly adjusted to meet market needs

Direct sales team in Class II&III hospitals OTC pharmacies coverage • 84 staff responsible for • 1,300 staff responsible for academic promotion of main 380.000 direct sales of key products products in Class II&III hospitals in OTC pharmacies 350,000 ■ 2019 ■ 2020 1H Collaborate with Jointown, 7,966 8,056 Kewei capsule Kewei granule expediting coverage in 5,934 6,271 2019 2020 1H pharmacies nationwide. **OTC** sales team 1,685 1,738 1,901 1,930 Class III hospital Class II hospital 20 staff responsible for distribution-based sales Class III hospital Class II hospital of non-core products in all healthcare **Direct sales team in primary healthcare** institutions institutions Primary healthcare **Distributors management team** institutions coverage • 1,323 staff responsible for academic 82,501 79,830 promotion in GP-based healthcare ■2019 institutions (Class I hospitals and Kewei sales distribution across channels 31,981^{33,806} community clinics) ■2020 1H **Primary healthcare** Kewei granule Kewei capsule 13% Class II&III (21% in 2019) E-commerce 45% Collaborate with Ali Health, 111 Inc and China (57% in 2019) Resources Pharm Commercial for expanding e-OTC commerce channel

E-commerce

(4% in 2019)

13%

Focus on online sales and promotion, online display and health big data analysis, aiming to promote brand recognition and increase market share

29%

(18% in 2019)



Contents







5

Business Review




R&D Pipeline








HCV and Diabetes – Targeting Critical Therapeutic Areas



HCV represents a market with unmet clinical demands and embedded potential. HEC has devised a holistic strategy with diversified product portfolio.



Oral form anti-HCV drug developed and launched by Chinese company

- All anti-HCV drugs currently developed by HEC are oral forms. Administered orally once a day, exhibiting a higher degree of compliance compared to pegylated interferon / ribavirin (PR) combination
- Anti-HCV drug portfolio covers genotype 1 and pan genotype hepatitis C

Established joint venture to expedite R&D progress

 Established JV to co-develop a new oral interferon-free DAAs combination therapy (Yimitasvir / Furaprevir)


Leading innovation supported by State Key Laboratory of anti-infection

- Acknowledged as National Key Anti-Infection Laboratory by Ministry of Science and Technology in 2015
- Comprehensive drug selection and evaluation platform and advanced team of R&D talents from China and overseas
- Research projects focusing on HCV, HBV and influenza

11

Source: China CDC website, IMS

Established team of 300 for academic promotion in endocrine/metabolic diseases, HEC provides better medication option with diversified portfolio spanning from 2nd and 3rd generation insulin, biosimilars and innovative new drugs.




🐣 蕉陽 羌谷

Launching generic products as scheduled, 15 generics expected to be approved to market in 2020 while 3 generics have been approved in 1H



Indication	Current status	Estimated approval in	2019 China market size (RMB mn) (All dosage form)	Originator company/Brand name	Number of brands passed BE*
Schizophrenia	Application submitted	2020	1,993	Eli Lily/Zyprexa	• 2
Parkinson's Disease	Application submitted	2020	72	Orion/Comtess	None
Depression	Application submitted	2020	613	Eli Lily/Cymbalta	• None
Depression	Application submitted	2020	977	Lundbeck/Cipralex	More than 3
Schizophrenia	Application submitted	2021	585	Otsuka/Abilify	• 1
Schizophrenia	Application submitted	2021	585	Otsuka/Abilify	• 1
es					
Type II diabetes	Approved to market	2020	220	BI/Trajenta	None
Type II diabetes	Application submitted	2020	294	Merck/-	• None
Type II diabetes	Application submitted	2020	0.57	BI/Jentadueto	• None
Type II diabetes	Application submitted	2020	101	Takeda/Nesina	• None
Hyperuricemia	Application submitted	2020	1,295	Astellas/Feburic	• None
Type II diabetes	Application submitted	2021	773	Merck/Januvia	None
ED, Pulmonary artery hypertension	Application submitted	2020	332	Eli Lily/Cialis	• 3
ED, Pulmonary artery hypertension	Application submitted	2021	1,478	Prizer/Viagra	• 1
Bladder overactivity	Application submitted	2022	44	Astellas/Vesicare	• 3
	Schizophrenia Parkinson's Disease Depression Depression Schizophrenia Schizophrenia Schizophrenia Type II diabetes Type II diabetes Type II diabetes Type II diabetes Type II diabetes D, Pulmonary artery hypertension	SchizophreniaApplication submittedParkinson's DiseaseApplication submittedDepressionApplication submittedSchizophreniaApplication submittedSchizophreniaApplication submittedSchizophreniaApplication submittedSchizophreniaApplication submittedType II diabetesApplication submittedFD, Pulmonary artery hypertensionApplication submittedFD, Pulmonary artery hypertensionApplication submittedFD, Pulmonary artery hypertensionApplication submitted	IndicationCurrent statusapproval inSchizophreniaApplication submitted2020Parkinson's DiseaseApplication submitted2020DepressionApplication submitted2020DepressionApplication submitted2020SchizophreniaApplication submitted2021SchizophreniaApplication submitted2021SchizophreniaApplication submitted2021SchizophreniaApplication submitted2020Type II diabetesApproved to market2020Type II diabetesApplication submitted2020Type II diabetesApplication submitted2020FD, Pulmonary artery hypertensionApplication submitted2020ED, Pulmonary artery hypertensionApplication submitted2020Finder and the stationApplication submitted2020Finder and the stationApplication submitted2020Finder and the stationApplication submitted2020FD, Pulmonary artery hypertensionApplication submitted2021	IndicationCurrent statusapproval in(RMB mn) (All dosage form)SchizophreniaApplication submitted20201,993Parkinson's DiseaseApplication submitted202072DepressionApplication submitted2020613DepressionApplication submitted2020977SchizophreniaApplication submitted2021585SchizophreniaApplication submitted2021585SchizophreniaApplication submitted2020220Type II diabetesApproved to market2020294Type II diabetesApplication submitted20200.57Type II diabetesApplication submitted2020101HyperuricemiaApplication submitted20201,295Type II diabetesApplication submitted20201,295Type II diabetesApplication submitted20201,295Type II diabetesApplication submitted2020332ED, Pulmonary artery hypertensionApplication submitted20211,478ED, Pulmonary artery hypertensionApplication submitted20211,478	IndicationCurrent statusapproval in (RMB mn) (All dosage form)Originator company/Brand nameSchizophreniaApplication submitted20201,993Eli Lily/ZyprexaParkinson's DiseaseApplication submitted202072Orion/ComtessDepressionApplication submitted2020613Eli Lily/CymbaltaDepressionApplication submitted2020977Lundbeck/CipralexSchizophreniaApplication submitted2021585Otsuka/AbilifySchizophreniaApplication submitted2020220Bl/TrajentaType II diabetesApplication submitted2020294Merck/-Type II diabetesApplication submitted20200.57Bl/JentaduetoType II diabetesApplication submitted2020101Takeda/NesinaHyperuricemiaApplication submitted20201,295Astellas/FeburicType II diabetesApplication submitted20201,295Astellas/FeburicType II diabetesApplication submitted20201,295Astellas/FeburicType II diabetesApplication submitted2020332Eli Lily/CialisED, Pulmonary artery PypertensionApplication submitted20211,478Prizer/Viagra

Pipeline replenished by Research Center, allowing HEC Pharm to selectively obtain high-valued products for commercialization in China



Priority Rights for Collaboration

- HEC Pharm has the priority to collaborate with the Research Center through license agreement for commercialization of selective new products in China.
- Renewal of collaboration agreement in plan by this year. HEC Pharm will be the commercialization and promotion platform for new products from Research Center.


Strong R&D team

- HEC Research Center had over 1,700 R&D staff, including 24 overseas experts and 1 officer of "Young Leadership Program" (青年领军人才).
- An experienced clinical research team currently consists of 220 staff.


Rich pipeline of new drugs

- 55 National Class 1.1 Innovative.
- 17 projects have been granted clinical trials approvals among which clinical trials for 13 projects have been initiated.
- 27 research projects granted as "the National Major Innovative Drug Projects" (国家新药创制重大专项) In the 11th, the 12th and the 13th Five Years Plan.

Number of projects in pipeline



Breakdown of innovative drug pipeline by therapeutic areas



Diversified new drug pipeline for future product replenishment (Selected projects)

		Project	Indication	Mechanism/target	Preclinical	Trial approval	Phase I	Phase II	Phase III	
A	Anti-viral	Morphathiadine	HBV	Capsid inhibitor						Clinical
n	ndocrine/ netabolic disease	HEC96719*	NASH	-						Preclinical
		Ningetinib	NSCLC	Axl/c-met/VEGFR2						
molecule	Oncology	Larotinib	HCC Esophageal cancer Pancreatic cancer	- EGFR -						
innovative new drugs		CT365	Solid tumor	PI3K/mTOR						
		CT413	Solid tumor	Axl/Mer						
Re	Respiratory	Yifenidone	IPF*	TNFα/TGFβ						
	tract	CT365	IPF*	PI3K/mTOR						
	diseases	Litapiprant	Asthma	CRTH2						
	CNS	HEC83518	Insomnia	Orexin receptor antagonist						
	CNS	HEC113995	Depression	5-HT reuptake inhibitor						
Er	ndocrine/	Insulin degludec	Type 2 diabetes	Insulin receptor						
n	netabolic	Dulaglutide	Type 2 diabetes	GLP-1						
	diseases	GLP-1/FGF21 agonist	Obesity/NASH/Diabetes	GLP-1/FGF21						
Biologics	Auto- immune	Adalimumab	Rheumatoid arthritis Ankylosing spondylitis	TNF inhibitor						
c	Oncology	Bevacizumab	Solid tumor	VEGF inhibitor						16

*IPF: Idiopathic pulmonary fibrosis





Contents







3

5

Business Review





Appendix



Financial Overview

	Six months ended 30 Jun		
(RMB million)	2020	2019	Change
Revenue	2,084	3,071	-32%
Gross profit	1,731	2,621	-34%
EBITDA	930	1,300	-29%
Operating profit	881	1,257	-30%
Net profit ¹	618	968	-36%
Adjusted net profit ²	696	1,096	-37%
Gross profit margin	83%	85%	-
EBITDA margin	45%	43%	-
Operating profit margin	42%	41%	-
Adjusted net profit margin ³	33%	36%	-
Basic/diluted EPS (RMB/share)	0.70/0.63	1.09/1.09	-
Proposed interim dividend ⁴ (RMB/share, tax inclusive)	0.1	1.0	-

(RMB million)	On 30 Jun 2020	On 31 st Dec 2019	Change
Total asset	10,460	9,912	6%
Total liability	5,486	5,289	4%
Net asset	4,974	4,623	8%
Cash and cash equivalents	3,346	2,779	20%

- Notes 1. Profit and total comprehensive income attributable to equity shareholders of the Company
- Profit and total comprehensive income attributable to equity shareholders of the Company (excluding the influence of the convertible bond)
 Based on adjusted net profit
- 4. Final dividend distribution is subject to approval of AGM decision





😃东陽光药

Acquired strategic investment by issuance of US\$400 million convertible bonds to Blackstone





.



As a long-term strategic investor, Blackstone will support the Company in its vision of becoming a leading Chinese pharmaceutical company and the preferred Chinese partner for international collaborations;

- Long-term funding to accelerate drug acquisitions and intrinsic business investment in support of future business growth, while maintaining stable dividend payout to shareholders. Proposed use of proceeds includes,
 - 1) Acquisition of drugs and other pharmaceutical products (including APIs)
 - 2) Capital expenditure on production facilities
 - 3) Expansion of sales and distribution networks
- Strategic partner to help drive implementation of global best practices and ensure continuous value creation for Company shareholders
 - Strengthening corporate governance via appointment of Blackstone director by co-nomination of non-executive director Dr. Zhao to the board of directors
 - 2) Establishing strategic partnerships with global pharmaceutical entities
 - 3) Improving IR functions and capital markets communication to raise company profile
- Establishment of Strategic Operating Committee and Drug Acquisition Committee to optimize the Company' s strategic direction and governance to ensure value maximization for all public shareholders

Subscription price	US\$ 400,000,000
Interest rate	3% per annum
Issue date (Completion date)	20 February, 2019
Maturity date	The seventh anniversary day of the Issue Date.
Conversion price	HK\$38 per conversion share (subject to adjustment)

Based on the initial conversion price of HK\$38 and assuming full conversion of the H Share convertible bonds at the initial conversion price, a maximum of 82,631,578 conversion shares will be allotted and issued, representing: (a) approximately 18.28% of the existing issued share capital of the Company as at the date of the Announcement; and (b) approximately 15.46% of the total share capital of the Company as enlarged by the issue of the Conversion Shares.

Blackstone

Dr. Zhao Dayao Biography

- Medical degree in neurology and pediatrics from Peking University Medical School, PhD in Science in Neurology from Harvard Medical School
- Previous experiences include general manager of Pfizer China R&D Center in Shanghai, Wuhan and Beijing, head of China R&D in Johnson&Johnson and group vice president at Genzyme














Appendix

😃东陽光药




Structure of the HEC group





HEC History and Milestones





Senior Management Team



Mr. JIANG Juncai Executive Director and General Manager

- Successively served as a researcher at the biochemistry division, a researcher and deputy head of the traditional Chinese medicine division and the deputy head of the zoological and botanical division of Sunshine Lake Pharma from July 2006 to May 2012
- Served as a director of Yidu HEC Industrial Development Co., Ltd. from March 2012 to May 2015
- He joined the Company serving as executive director in May 2015

Mr. TANG Xinfa Chairman and Non-Executive Director

- Joined the Company in May 2015, and also serving as the Chief Officer of the State Key Laboratory of New Drug Research and Development for anti-virus
- Joined Shenzhen HEC Industrial in 2002, having served senior management positions at Sunshine Lake Pharma, Ruyuan HEC Pharma, Linzhi HEC Pharmaceutical Investment, and Dongguan HEC Research
- He has 15 years of management experience
- Received a master degree from Xiamen University in September 2002

Mr. CHEN Yangui Executive Director

and Director of Sales Department

- Joined Dongguan HEC Research in October 2005, and successively held several different managing positions in company
- He joined the Company in May 2014 and has been serving as executive director since May 2015

	Mr. WANG Danjin	Executive Director, Deputy General Manager		
	Mr. LI Shuang	Executive Director, Deputy General Manager		
t	Mr. ZHANG Qiang	Chief Financial Officer		
S /	Mr. PENG Qiyun	Secretary of the Board		



Disclaimer

This document does not constitute an offer or invitation to purchase or subscribe for any securities and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation thereto.

The information in this presentation has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of any information or opinion contained herein. None of the company, or any of their respective directors, officers, employees, agents or advisers shall be in any way responsible for the contents hereof, or shall be liable whatsoever (in negligence or otherwise) for any loss or damage whatsoever arising from using of the information contained in this presentation or otherwise arising in connection therewith and none of them shall owe you any fiduciary duty in relation to this presentation.

This presentation may contain forward-looking statements. Any such forward-looking statements are based on a number of assumptions about the operations of the company and factors beyond the company' s control and are subject to significant risks and uncertainties, and accordingly, actual results may differ materially from these forward-looking statements. The company undertakes no obligation to update these forward-looking statements for events or circumstances that occur subsequent to such dates.



Thank You!

Our mission —— For everyone's health

For more information, please visit the company website - cj.hec.cn